These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33198433)

  • 1. Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia.
    Park R; Kim S; Kim E
    Psychiatry Investig; 2020 Nov; 17(11):1158-1165. PubMed ID: 33198433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.
    Rajji TK; Mulsant BH; Davies S; Kalache SM; Tsoutsoulas C; Pollock BG; Remington G
    Am J Psychiatry; 2015 Jun; 172(6):579-85. PubMed ID: 25859763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model.
    Dal Santo F; Jarratt-Barnham I; González-Blanco L; García-Portilla MP; Bobes J; Fernández-Egea E
    Eur Neuropsychopharmacol; 2020 Apr; 33():158-163. PubMed ID: 32057590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.
    Molins C; Carceller-Sindreu M; Navarro H; Carmona C; Piñeiro M; Martínez E; Álvarez E; Portella MJ
    Psychiatry Res; 2017 Dec; 258():153-157. PubMed ID: 29024893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
    Sarpal DK; Blazer A; Wilson JD; Calabro FJ; Foran W; Kahn CE; Luna B; Chengappa KNR
    Schizophr Res; 2022 May; 243():170-177. PubMed ID: 35381515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia.
    Costa-Dookhan KA; Rajji TK; Tran VN; Bowden S; Mueller DJ; Remington GJ; Agarwal SM; Hahn MK
    Sci Rep; 2021 Jan; 11(1):2004. PubMed ID: 33479273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.
    Sporn AL; Vermani A; Greenstein DK; Bobb AJ; Spencer EP; Clasen LS; Tossell JW; Stayer CC; Gochman PA; Lenane MC; Rapoport JL; Gogtay N
    J Am Acad Child Adolesc Psychiatry; 2007 Oct; 46(10):1349-1356. PubMed ID: 17885577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine and global cognition in schizophrenia.
    Rajji TK; Uchida H; Ismail Z; Ng W; Mamo DC; Remington G; Pollock BG; Mulsant BH
    J Clin Psychopharmacol; 2010 Aug; 30(4):431-6. PubMed ID: 20631560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus.
    Ertuğrul A; Ozdemir H; Vural A; Dalkara T; Meltzer HY; Saka E
    Brain Res Bull; 2011 Feb; 84(2):144-50. PubMed ID: 21134422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
    Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
    Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
    [No Abstract]   [Full Text] [Related]  

  • 11. Variability of the in vivo metabolism of clozapine.
    Raedler TJ; Hinkelmann K; Wiedemann K
    Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.
    Li Z; Huang M; Ichikawa J; Dai J; Meltzer HY
    Neuropsychopharmacology; 2005 Nov; 30(11):1986-95. PubMed ID: 15900318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia.
    Kır Y; Baskak B; Kuşman A; Sayar-Akaslan D; Özdemir F; Sedes-Baskak N; Süzen HS; Baran Z
    Psychiatry Res Neuroimaging; 2020 Sep; 303():111128. PubMed ID: 32593951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions.
    Maehara S; Okuda S; Ohta H
    Brain Res Bull; 2011 Oct; 86(3-4):146-51. PubMed ID: 21855612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-desmethylclozapine: is there evidence for its antipsychotic potential?
    Mendoza MC; Lindenmayer JP
    Clin Neuropharmacol; 2009; 32(3):154-7. PubMed ID: 19483482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia.
    Islam F; Maciukiewicz M; Freeman N; Huang E; Tiwari A; Mulsant BH; Pollock BG; Remington G; Kennedy JL; Müller DJ; Rajji TK
    J Psychopharmacol; 2021 Jan; 35(1):31-39. PubMed ID: 33143542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with cognitive dysfunction in treatment-responsive and -resistant schizophrenia: A pilot cross-sectional study.
    Suzuki Y; Watanabe K; Kanno-Nozaki K; Horikoshi S; Ichinose M; Hirata Y; Kobayashi Y; Takeuchi S; Osonoe K; Hoshino S; Miura I
    J Psychiatr Res; 2024 Oct; 178():228-235. PubMed ID: 39163661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
    Weiner DM; Meltzer HY; Veinbergs I; Donohue EM; Spalding TA; Smith TT; Mohell N; Harvey SC; Lameh J; Nash N; Vanover KE; Olsson R; Jayathilake K; Lee M; Levey AI; Hacksell U; Burstein ES; Davis RE; Brann MR
    Psychopharmacology (Berl); 2004 Dec; 177(1-2):207-16. PubMed ID: 15258717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological evidence showing muscarinic agonist-antagonist activities of N-desmethylclozapine using hippocampal excitatory and inhibitory neurons.
    Sugawara Y; Kikuchi Y; Yoneda M; Ohno-Shosaku T
    Brain Res; 2016 Jul; 1642():255-262. PubMed ID: 27048752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice.
    Wiebelhaus JM; Vunck SA; Meltzer HY; Porter JH
    Behav Pharmacol; 2012 Jun; 23(3):262-70. PubMed ID: 22547022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.